TBPH — Theravance Biopharma Share News
0.000.00%
Last trade - 00:00- $857.84m
- $495.97m
- $107.46m
Theravance Biopharma Inc expected to post a loss of 17 cents a share - Earnings Preview
Theravance Biopharma Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Theravance Biopharma Expects To Complete Pifr-2 Study And Provide Top-Line Results In 2H 2023
Brief: Theravance Biopharma CFO Andrew Hindman Steps Down
Brief: Theravance Biopharma Announces Preliminary Results Of Tender Offer
Theravance Biopharma Inc reports results for the quarter ended in September - Earnings Summary
Brief: Theravance Biopharma Inc Reports Third Quarter 2022 Financial Results
Theravance Biopharma Inc expected to post a loss of 18 cents a share - Earnings Preview
Theravance Biopharma Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: Theravance Biopharma Announces Tender Offer For Up To $95 Million Of Its Ordinary Shares
Theravance Biopharma up on $250 mln capital return program
Brief: Theravance Biopharma Initiates $250 Mln Capital Return Program
Brief: Theravance Biopharma Inc QTRLY Loss Per Share $0.11
Theravance Biopharma Inc expected to post earnings of 11 cents a share - Earnings Preview
Brief: Theravance Biopharma Announces Tender Offer For Outstanding 3.25% Convertible Senior Notes Due 2023
Brief: Theravance Biopharma To Sell Trelegy Ellipta Royalty Interests To Royalty Pharma For About $1.1 Bln In Upfront Cash With Over $1.5 Bln In Potential Total Value
Theravance Biopharma Inc reports results for the quarter ended in March - Earnings Summary
Brief: Theravance Biopharma, Inc. Reports First Quarter 2022 Financial Results
Theravance Biopharma Inc expected to post a loss of 11 cents a share - Earnings Preview